In Senate probe, Sanofi claims Dengvaxia 'safe, effective'

Patrick Quintos, ABS-CBN News

<figure class="op-interactive"><div id="IVS_ABS_Body_Video_1_Container"> <ivs-player id="IVS_ABS_Body_Video_1" data-ivs-spid="3001339" data-ivs-key="e8c22c015ca9eafa76f1e3edfa03c603" data-ivs-vid="1444023" data-ivs-floating="1"></ivs-player> <script src="https://player.ivideosmart.com/ivsplayer/v4/dist/js/iframe-parent.js"></script> <script src="https://player.ivideosmart.com/ivsplayer/v4/dist/js/loader.js"></script> </div></figure><div class="iwantbar">Watch more in <a href="~//www.iwantv.com.ph/">iWantv</a> or <a href="~//tfc.tv/">TFC.tv</a></div><p>MANILA - French drug-maker Sanofi Pasteur assured Filipinos that its dengue vaccine Dengvaxia continues to be safe, despite a recent admission that the drug may be harmful when administered to individuals not previously infected with dengue.</p><p>Speaking before senators, Sanofi&#x27;s Thomas Triomphe said there have been no deaths linked to the controversial dengue vaccine, which is still being used in 11 other countries.</p><p>&quot;We at Sanofi assure Filipinos that Dengvaxia continues to be a safe and efficacious vaccine,&quot; he said, stressing that the vaccine was a product of 20 years of rigorous development.</p><div class="embed-wrap"><figure data-feedback="fb:likes,fb:comments"><img src="http://sa.kapamilya.com/absnews/abscbnnews/media/2017/news/12/11/20171211-thomas-triomphe-jc.jpg?ext=.jpg"/><figcaption>Representative of Paris based pharmaceutical company Sanofi-Pasteur, Thomas Triumphe Head for Asia Pacific answers questions during the senate inquiry on the Dengvaxia vaccine. <em>Jonathan Cellona, ABS-CBN News</em></figcaption></figure></div><p>Triomphe said Sanofi has high ethics standard and compliance and that he sees no negligence on the part of the company.</p><p>Dengvaxia has been administered to over 800,000 Filipino children as part of a program initiated during the administration of President Benigno Aquino III. </p><p>The vaccines expire in 3 years, Triomphe said. The vials in the Philippines, he added, expire by May and August 2018, depending on the batch.</p><p>The health scare started when Sanofi revealed that the vaccine may cause more severe symptoms on those who had not been previously infected by dengue.</p><ul class="op-related-articles">	<li><a href="http://news.abs-cbn.com/news/11/30/17/doh-on-alert-as-sanofi-admits-dengue-vaccine-poses-risks">DOH on alert as Sanofi admits dengue vaccine poses risks</a></li></ul><p>Despite this, Sanofi insists Dengvaxia will help reduce cases of dengue in the Philippines, stressing that the effectiveness of the vaccines is backed by science.</p><p>&quot;Even today, there has been no one -- not one single death causally linked to the vaccine,&quot; said Triomphe. </p>

<p>Sanofi insists Dengvaxia will help reduce cases of dengue in the Philippines, stressing that the effectiveness of the vaccines is backed by science.</p>

Sanofi insists Dengvaxia will help reduce cases of dengue in the Philippines, stressing that the effectiveness of the vaccines is backed by science.

In Senate probe, Sanofi claims Dengvaxia 'safe, effective' | ABS-CBN

Halalan 2025

Entertainment

News

Metro.Style

Lifestyle

Sports

More

Traffic

Horoscope

News

In Senate probe, Sanofi claims Dengvaxia 'safe, effective'

In Senate probe, Sanofi claims Dengvaxia 'safe, effective'

Patrick Quintos,

ABS-CBN News

Published Dec 11, 2017 03:08 PM PHT

|

Updated Dec 11, 2017 03:53 PM PHT

Read More:

Dengue

Vaccine

Sanofi

Dengvaxia

Senate

Probe

Health

DOH

Philippines

ABS-CBN is the leading media and entertainment company in the Philippines, offering quality content across TV, radio, digital, and film. Committed to public service and promoting Filipino values, ABS-CBN continues to inspire and connect audiences worldwide.

Corporate

Investors

Governance

International Distribution

Corporate

Governance

Investors

International Distribution

NPC Seal of Registration

Privacy Policy

AI Policy

Terms of Service

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.